BUX — BioMark Diagnostics Balance Sheet
0.000.00%
Last trade - 00:00- CA$36.78m
- CA$37.24m
- CA$0.16m
- 13
- 12
- 63
- 19
Annual balance sheet for BioMark Diagnostics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.612 | 0.878 | 0.383 | 0.072 | 0.157 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.016 | 0.027 | 0.082 | 0.034 | 0.043 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.628 | 0.923 | 0.499 | 0.126 | 0.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.009 | 0.027 | 0.969 | 0.589 | 0.852 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 0.637 | 0.953 | 1.47 | 0.732 | 1.09 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.08 | 0.922 | 1.5 | 1.66 | 1.24 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1.08 | 1.03 | 2.11 | 1.88 | 1.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -0.439 | -0.079 | -0.636 | -1.15 | -0.61 |
| Total Liabilities & Shareholders' Equity | 0.637 | 0.953 | 1.47 | 0.732 | 1.09 |
| Total Common Shares Outstanding |